GB2475660B - Methods and kit for treating cluster headache disorders - Google Patents

Methods and kit for treating cluster headache disorders

Info

Publication number
GB2475660B
GB2475660B GB1104907.9A GB201104907A GB2475660B GB 2475660 B GB2475660 B GB 2475660B GB 201104907 A GB201104907 A GB 201104907A GB 2475660 B GB2475660 B GB 2475660B
Authority
GB
United Kingdom
Prior art keywords
kit
methods
cluster headache
headache disorders
treating cluster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1104907.9A
Other languages
English (en)
Other versions
GB201104907D0 (en
GB2475660A (en
Inventor
John H Halpern
Torsten Harry Johannes Passie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hannover Medical School
McLean Hospital
Original Assignee
Hannover Medical School
McLean Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hannover Medical School, McLean Hospital filed Critical Hannover Medical School
Publication of GB201104907D0 publication Critical patent/GB201104907D0/en
Publication of GB2475660A publication Critical patent/GB2475660A/en
Application granted granted Critical
Publication of GB2475660B publication Critical patent/GB2475660B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB1104907.9A 2008-09-17 2009-09-04 Methods and kit for treating cluster headache disorders Expired - Fee Related GB2475660B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9777308P 2008-09-17 2008-09-17
PCT/US2009/055971 WO2010033392A2 (en) 2008-09-17 2009-09-04 Methods and kits for treating cluster headache disorders

Publications (3)

Publication Number Publication Date
GB201104907D0 GB201104907D0 (en) 2011-05-04
GB2475660A GB2475660A (en) 2011-05-25
GB2475660B true GB2475660B (en) 2013-04-17

Family

ID=42040074

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1104907.9A Expired - Fee Related GB2475660B (en) 2008-09-17 2009-09-04 Methods and kit for treating cluster headache disorders

Country Status (10)

Country Link
US (2) US8415371B2 (enExample)
EP (1) EP2331100B1 (enExample)
JP (1) JP5690732B2 (enExample)
CN (1) CN102164603B (enExample)
BR (1) BRPI0918623A2 (enExample)
CA (1) CA2737135C (enExample)
GB (1) GB2475660B (enExample)
IL (1) IL211714A (enExample)
MX (1) MX2011002883A (enExample)
WO (1) WO2010033392A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
BRPI0918623A2 (pt) * 2008-09-17 2015-12-01 Hannover Med Hochschule métodos e kits para tratar distúrbios de cefaleia em grupo
US12616706B2 (en) * 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
US12594272B2 (en) 2020-03-25 2026-04-07 Ceruvia Lifesciences Llc 2-bromo-lysergic acid diethylamide for substance abuse
US20240058326A1 (en) * 2020-12-22 2024-02-22 Betterlife Pharma Inc. Methods of treating mental or mood disorders using 2-bromo-lsd
US20240180894A1 (en) * 2021-03-22 2024-06-06 Betterlife Pharma Inc. Methods of treating mental and/or mood disorders using 2-bromo-lsd alone or in combination with a mtor inhibitor
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
US20230064429A1 (en) 2021-08-19 2023-03-02 Mind Medicine, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US20230219955A1 (en) 2021-09-20 2023-07-13 Betterlife Pharma Inc. Lsd derivatives, synthesis & method for treatment of diseases and disorders
ES3066618T3 (en) * 2022-12-31 2026-05-13 Ceruvia Lifesciences Llc Salts of 2-bromolysergic acid diethylamide
WO2024145546A1 (en) 2022-12-31 2024-07-04 Ceruvia Lifesciences Llc Process for synthesizing 2-bromolysergic acid diethylamide via controlled bromination of lysergic acid
EP4642780A2 (en) * 2022-12-31 2025-11-05 Ceruvia Lifesciences LLC Process for synthesizing 2-bromolysergic acid diethylamide via controlled hydrolysis of bromocriptine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264456A1 (en) * 2008-03-21 2009-10-22 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders asociated with cephalic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228959A (en) * 1962-01-16 1966-01-11 Geigy Chem Corp Quaternary salts of certain indolealkylamines and therapeutic uses thereof
US4524072A (en) * 1984-06-18 1985-06-18 Zivin Justin A Reduction of stroke damage
GB8618700D0 (en) * 1986-07-31 1986-09-10 Beecham Group Plc Compounds
DE3785507T2 (de) * 1986-07-31 1993-07-29 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
HRP20040846A2 (en) * 2002-02-26 2005-06-30 Ortho-Mcneil Pharmaceutical Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
BRPI0918623A2 (pt) * 2008-09-17 2015-12-01 Hannover Med Hochschule métodos e kits para tratar distúrbios de cefaleia em grupo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264456A1 (en) * 2008-03-21 2009-10-22 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders asociated with cephalic pain

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
California medicine 1961 vol.95 No.3 Friedman A P "Headache pharmacological approach to treatment" pages 145-149 *
Circulation vol. 16 Schneckloth R et al "Effects of serotonin antagonists in normal subjects and patients with carcinoid tumors" pages 523-532 see whole document *
Heacache vol. 16 [1976], Sicuteri F "Migraine a central biochemical dysnociception", pages 145-159, See page 150 right column last sentence, page 156 left column last paragraph *
Neurology vol. 66 [2006], Sewell AR et al "Respone of cluster headache to psilocybin and LSD", pages 1920-1922 See abstract page 1920 right column line 38, 41-42, 56-57 *
The Journal of Pharmacology and experimental therapeutics [1982] Hervey J A et al "Effects of dLysergic acid diethylamide d-2-Bromolysergic acid diethylamide, dl-2, 5-dimethoxy-4-methylamphetamine and d-Amphetamine on classical conditioning of the rabbit nictitating membrane response", pages 289-294 *

Also Published As

Publication number Publication date
MX2011002883A (es) 2011-04-21
JP2012502909A (ja) 2012-02-02
CN102164603A (zh) 2011-08-24
BRPI0918623A2 (pt) 2015-12-01
WO2010033392A2 (en) 2010-03-25
US20110104275A1 (en) 2011-05-05
CA2737135A1 (en) 2010-03-25
CN102164603B (zh) 2015-11-25
IL211714A0 (en) 2011-06-30
GB201104907D0 (en) 2011-05-04
CA2737135C (en) 2017-07-11
HK1161098A1 (zh) 2012-08-24
US8415371B2 (en) 2013-04-09
WO2010033392A3 (en) 2010-06-17
EP2331100B1 (en) 2014-07-16
EP2331100A2 (en) 2011-06-15
GB2475660A (en) 2011-05-25
EP2331100A4 (en) 2012-04-25
JP5690732B2 (ja) 2015-03-25
US20130252996A1 (en) 2013-09-26
IL211714A (en) 2016-04-21

Similar Documents

Publication Publication Date Title
GB201104907D0 (en) Methods and kit for treating cluster headache disorders
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
IL257418A (en) Methods for treating addiction
EP2331088A4 (en) COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
GB2467710B (en) Methods for treating social disorders
PL2894165T3 (pl) Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
IL212986A0 (en) Methods for treating eye disorders
IL213526A0 (en) Methods for treating acute myocardial infarctions and associated disorders
EP2309858A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL208069A0 (en) Methods for treating psoriasis
EP2323579A4 (en) METHODS AND DEVICES FOR TREATING PRESBYOPIA
EP2142206A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
IL199739A0 (en) Methods for treating psoriasis
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
PL2131841T3 (pl) Sposoby leczenia bólu ostrego
EP2219650A4 (en) COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS
PT2201950T (pt) Compostos e métodos para tratar doenças do espetro do autismo
IL194373A0 (en) Methods for treating kidney disorders
IL207906A0 (en) Treatment for ocular-related disorders
GB0718824D0 (en) Methods of treating lysosomal storage disorders
AU2008902365A0 (en) Methods for treating muscle disorders and improving muscle form
ZA200801796B (en) Methods for treating substance-related disorders
ZA201000867B (en) Methods for treating dependence

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20150904